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DC is an inherited bonemarrow failure syndrome (BMF)with
a high predisposition to cancer development. The HSCT is the
only curative treatment for BMF associated but imposes
signiﬁcant toxicity. We reported the outcome of 12 pts who
underwent bone marrow transplantation for DC between
July 1993 and May 2013 in a single institution. The median
age at transplantationwas 16,5 years (range 3 to 27). Two pts
had the non classical forms of disease (Revesz syndrome and
severe aplastic anemia with evidence of short telomeres).
Five pts received bone marrow from their HLA matched
siblings and were conditioned with Cyclophosphamide (CY)
200mg/Kg. Seven pts were transplanted from unrelated do-
nors (URD): 6 BM (match 10/10: 4pts and 9/10: 2pts) and 1
CB (5/6). Conditioning Regimen for the URD BMT was CY30-
60mg/Kg + Fludarabine125mg/m2 + rabbitATG5mg/Kg and
CB Busulfan12mg/Kg + Fludarabine125mg/m2 + rATG5mg/
Kg. Graft versus host disease (GVHD) prophylaxis: metho-
trexate and cyclosporine for all patients, except for the one
who received CBU. Median of TNC: BM: 3.97 x 108/Kg. CBU:
6.5 x107/Kg. All pts survived more than 28 days and were
available for engraftment. All but one pt had stable hema-
tological engraftment. Chimerismwas complete in 7 patients
and mixed in the other 5 patients. Mucositis was the only
toxicity observed (grade II in 5 pts and grade III in 2 pts).
GVHD was observed only among unrelated transplants. Two
pts developed grade II acute GVHD and both progressed to
chronic GVHD (limited). The probability of survival in 2 year
was 50%. Two deaths were related to the procedure (SOS and
adenovirus sepsis). Four pts died between 1 and 10 years
after transplant because of progression of underlying dis-
ease. Six patients (4 recipients of an URD) are alive between 6
months and 11 years after transplant with a median follow
up of 1.6 years.
Conclusions: Regimen related toxicity was very low and an
appropriate engraftment was achieved. Late mortality was
consequent to the progression of underlying disease. Long
term follow up is essential in order to detect late complica-
tions related to the transplant procedure or the underlying
disease.375
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of Wisconsin, Milwaukee, WIHistiocytic disorders are rare but often fatal illnesses. Within
these, familial and secondary hemophagocytic lymphohis-
tiocytosic disorders (HLH) are primarily diagnosed in child-
hood, and there have been few large analyses of outcomes in
adults with HLH. The widely-accepted HLH-94 treatment
regimen consisting of dexamethasone, etoposide and cyclo-
sporine therapy followed by allogeneic stem cell trans-
plantation (SCT) has been employed primarily in children. In
the largest series to date of 113 children under 15 years of
age, a 3 year survival rate of 55% overall and 62% for those
receiving allogeneic SCT was seen (Henter. Blood 2002;
100:2367-2372). In light of the highly proinﬂammatory
cytokine environment that characterizes HLH, alemtuzumab
for profound lymphocyte depletion in concert with condi-
tioning for pediatric SCT is becoming increasingly common,
with an impact on rates of acute GvHD andmixed chimerism
reported. (Marsh. Blood 2010;116:5824-5831; Marsh. Pediatr
Blood Cancer 2013;60:101-109). To assess current practices
and outcomes in adults, we performed a retrospective re-
view using the CIBMTR database of all subjects over 18 years
of age receiving allogeneic SCT for histiocytic conditions
between 2001 and 2012.
Results: 47 subjects were identiﬁed, 16 of whom were
transplanted in 2011 or 2012. Median age was 25 (18-67).
Underlying diagnoses were familial HLH (47%), secondary
HLH (32%), malignant histiocytosis (15%), and histiocytic
disorders not otherwise speciﬁed (6%). 31 subjects (66%)
received transplants from unrelated donors. 26 subjects
(55%) received PBSCs. The remaining subjects received bone
marrow, except for one who received umbilical cord blood.
26 subjects (56%) received myeloablative conditioning, pri-
marily cytoxan-TBI-based or cytoxan and busulfan. 21 sub-
jects underwent reduced-intensity or non-myeloablative
conditioning with ﬂudarabine-based regimens. 18 subjects
(38%) underwent conditioning in combination with alem-
tuzumab. Kaplan-Meier survival rate estimates for the entire
cohort were 93% at 100 days (95% CI, 71-93), 60% at one year
(95% CI, 45-75) and 57% at 2 years (95% CI, 40-72).
Conclusions: Adults with histiocytic disorders, primarily
HLH, have survival rates after allogeneic SCT similar to those
seen in the pediatric literature. Inclusion of alemtuzumab
prior to or in concert with conditioning is common in adults.
Allogeneic SCT regimens for HLHmerit prospective studies in
adults as well as children. We encourage participation in the
BMT-CTN 1204 study, a phase II study of reduced-Intensity
conditioning for children and adults with hemophagocytic
syndromes or selected primary immune deﬁciencies pre-
ceded by alemtuzumab therapy.376
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Complications of allogeneic stem cell transplant, such as
infection, relapse and GvHD, are linked to failure of balanced
immune reconstitution. Early quantiﬁcation of immunologic
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emptive therapies. We hypothesize that T-cell receptor (TCR)
diversity after double umbilical cord blood transplantation
(dUCBT) will predict clinical outcomes.
Methods: 42 adult dUCBT recipients received ﬂudarabine,
melphalan, ATG with tacrolimus/sirolimus as GvHD pro-
phylaxis. TCRb CDR3 regions were ampliﬁed from unsorted
PBMCs and sequenced using the ImmunoSeq platform
(Adaptive Biotechnologies) at 3, 6 and 12 months after
dUCBT. Samples analyzed had predominantly donor T-cell
chimerism and no morphologic relapse. We analyzed 34
samples at 3 mos, 26 at 6 mos and 23 at 12 mos. Entropy/
Shannon’s diversity index and richness/Fisher’s alpha di-
versity were calculated from number and frequency of TCRb
sequences and normalized for sequencing depth. Higher
entropy and richness, measures of uncertainty and unseen
species within a complex population, reﬂect increased
diversity.
Results: Median age was 52 years (19-67). 57.1% were in
remission at dUCBT. Primary indications for dUCBT were
AML, NHL and MDS. Median follow-up among survivors was
47 months (18-91). 4-year OS was 41%; 4-year PFS was 26%.
As a whole, dUCBT recipients increased entropy and richness
of their T cell repertoire in the ﬁrst year. We categorized
subjects into 3 groups: relapse, NRM, or alive with neither
event. In the NRM cohort, median entropy and richness
values rose slightly from 3 to 6 mos then fell at 12 mos. In
comparison, median entropy and richness were higher in the
no event cohort between 3 and 12mos and rose substantially
to diversity levels found in healthy donors. (p¼0.01, 0.09,
0.004 for entropy at 3,6,12 mos; p¼0.06, 0.11, 0.006 for
richness at 3,6,12 mos). (Figure) Entropies of subjects who
relapsed did not differ from those of the no event cohort (not
depicted). In a similar analysis, entropy values for subjects
with chronic GvHD fell between 3 and 12 mos and were
signiﬁcantly lower than in subjects without any cGvHD,
relapse, or NRM at 12 mos (median entropy 5.9 vs 12.3,
p¼0.04). Inmultivariable analyses controlling for age, patient
sex, disease status, and diagnosis, high entropy was associ-
ated with lower NRM (HR 0.68, p<0.001), PFS (HR 0.79,
p¼0.009) and OS (HR 0.73, p¼0.005). High richness (log10
transformed) was associated with lower NRM (HR 0.3,
p<0.001) and OS (HR 0.30, p¼0.0003).
Conclusion: T-cell repertoire diversity as early as 3 months
after dUCBT is signiﬁcantly lower in subjects who eventuallyexperience NRM or cGvHD and does not expand with time
after transplant. These quantitative predictive indicesmay be
used to identify dUCBT recipients who merit more intensive
monitoring or prophylactic strategies against infection and
GvHD.377
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Background: Monitoring of cytomegalovirus (CMV) DNA by
PCR followed by preemptive treatment of CMV viremia
(CMVV) is an acceptable preventive strategy to reduce the
incidence of CMV tissue invasive disease (TID) after alloge-
neic hematopoietic cell transplant (HCT). Despite proactive
monitoring, some patients develop CMV TID leading to
adverse outcomes. We seek to characterize risk factors
associated with the development of CMV TID in HCT re-
cipients who were monitored and treated preemptively.
Methods: We reviewed the charts of 256 adult HCT re-
cipients, actively monitored for CMVV between January 1,
2009 and July 31, 2013. Our center preemptively monitors
allogeneic HCT recipients with weekly CMVDNA by PCR until
Day + 100, and thereafter every 2 weeks in patients with
GVHD. Antiviral therapy was initiated within 1 day of iden-
tifying signiﬁcant CMVV. Patients with CMV TID occurring
during preemptive monitoring were matched 1:1 by the
underlying disease, year of transplant, and time of follow-up
with controls that developed CMVV without TID.
Results: Of the 15 patients that developed CMV TID despite
preemptive therapy, 10 (66.7%) occurred within the ﬁrst 100
days following HCT. Median time from HCT to CMV TID was
62 days (range 25 -1137). All cases were gastrointestinal CMV
TID with 1 case of CMV-associated oral mucositis. 9/15 (60%)
had concurrent CMVV at the time of CMV TID diagnosis, and
4/15 (26%) were preemptively being treated with antivirals
for CMVV at the time of CMV TID diagnosis. The mean viral
load was 1,738.5 copies DNA/mL, range (0-9,699 copies DNA/
mL). 6/15 (40%) had at least one prior episode of CMVVwhich
had previously resolved. When compared with controls
there were no signiﬁcant differences in age, type of HCT, time
to CMV TID, conditioning therapy, donor matching, comor-
bidities, GVHD, level of initial CMVV, or CMV donor/recipient
serological status. No ganciclovir resistance was identiﬁed in
patients with CMV TID.
Conclusions: All cases of CMV TID were gastrointestinal
disease and tended to occur early after HCT. CMV TID
developed in the majority without preceding viremia. There
were no risk factors that could speciﬁcally identify patients
likely to develop CMV TID despite pre-emptive monitoring
and treatment. Gastrointestinal CMV TID remains an
inherent complication of a CMV preemptive strategy.378
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